Involving Phosphatase Patents (Class 435/21)
-
Patent number: 6472516Abstract: Isolated DNA molecules are disclosed corresponding to a novel progestin-regulated gene (PRG1). The PRG1 polypeptide (PRG1) and uses thereof are also described, and include assays for assessing progestin-responsiveness in a subject.Type: GrantFiled: April 24, 1998Date of Patent: October 29, 2002Assignee: The Garvan Institute of Medical ResearchInventors: Colin Kenneth William Watts, Jenny Ann Hamilton
-
Patent number: 6472193Abstract: An object of the present invention is to provide a recombinant LPA phosphates capable of specifically hydrolyzing LPA, which is useful for elucidation of the metabolic pathway of LPA, and also for diagnosis and treatment of various diseases with which LPA is associated. The present invention also provides for a method capable of simply and inexpensively determining LPA associated with various diseases. The present invention also provides for a kit for determination suitable for the method. The present invention has succeeded in purifying the LPA phosphatase using bovine brain as a raw material, and further in cloning human LPA phosphatase gene.Type: GrantFiled: September 11, 2000Date of Patent: October 29, 2002Assignee: Azwell Inc.Inventors: Tadaomi Takenawa, Masami Hiroyama, Tatsuya Kishimoto, Masahiro Yamaguchi, Mitsuyoshi Toyosato, Kouji Mizuno
-
Patent number: 6468760Abstract: The present invention provides high throughput screening systems for identifying antifungal compounds. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts.Type: GrantFiled: November 28, 2000Date of Patent: October 22, 2002Assignee: Cytokinetics, Inc.Inventors: Corey E. Nislow, Roman Sakowicz, Christophe Beraud
-
Patent number: 6465259Abstract: A method for quantitatively and/or qualitatively assaying an analyte in a sample, wherein the analyte is a receptor binding compound, has low detection limits equivalent to those of radioreceptor assays. The method comprises the steps of a) contacting the sample with material comprising a receptor for the analyte in order for receptor-analyte binding to occur and b) further contacting the sample with a detectable ligand for the receptor in order for receptor-ligand binding to occur, followed by c) separating the resulting receptor bound and free fractions, d) subjecting the receptor bound fraction to dissociating conditions releasing the ligand from the receptor and e) assaying for the dissociated ligand in a manner known per se for the detection of the detectable ligand.Type: GrantFiled: May 6, 1999Date of Patent: October 15, 2002Assignee: Merska B.V.Inventors: Maria Johanna Janssen, Kornelis Ensing, Rokus Arie De Zeeuw
-
Publication number: 20020146695Abstract: A method for detecting whether methyladenosine phosphatase (MTAse) is present in a cell sample. In one respect, the method comprises adding oligonucleotide probes to the sample, which probes are capable of specifically hybridizing to any MTAse encoding nucleic acid in the sample under conditions favoring that hybridization. Absence of MTAse in a sample is considered to be indicative of malignancy. Polynucleotides encoding MTAse, MTAse peptides and antibodies to MTAse, as well as kits for performing the methods of the invention, are provided.Type: ApplicationFiled: February 9, 2001Publication date: October 10, 2002Inventors: Tsutomu Nobori, Dennis A. Carson, Kenji Takabayashi
-
Patent number: 6458532Abstract: Methods and compositions are provided for determining a genotype associated with increased susceptibility to manic-depressive illness. The genotype is determined using markers for a region of chromosome 18 exhibiting linkage disequilibrium with manic-depressive illness. The invention also provides for a novel myo-inositol monophosphatase protein encoded for on chromosome 18.Type: GrantFiled: April 19, 1999Date of Patent: October 1, 2002Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Sevilla D. Detera-Wadleigh, Takeo Yoshikawa, Alan R. Sanders, Lisa E. Esterling
-
Patent number: 6455290Abstract: The present invention provides a human polypeptide homolog of human tankyrase protein (THP) and polynucleotides which identify and encode THP. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of THP agonists/antagonists, useful for the treatment of human diseases, such as human cancer and age related diseases.Type: GrantFiled: July 9, 1999Date of Patent: September 24, 2002Assignee: Pharmacia Italia S.p.A.Inventors: Jens Berthelsen, Salvatore Toma, Antonella Isacchi
-
Patent number: 6455026Abstract: The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents that specifically bind to human protein tyrosine phosphatase-zeta (PTP&zgr;) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.Type: GrantFiled: March 23, 2001Date of Patent: September 24, 2002Assignee: AGY Therapeutics, Inc.Inventors: Sabine Mueller, Thorsten Melcher, Daniel J. Chin
-
Publication number: 20020132263Abstract: The invention relates to a method of detecting and/or assaying nucleoside hydrolases or nucleoside phosphorylases using a chromogenic substrate. Preferred chromogenic substrates have formula (I) where X is OH, or H, and Y is the residue of Y—OH where Y—OH is a chromophore or a compound readily converted to a chromophore and the substrates are hydrolysed by the nucleoside hydrolase to yield ribose or 2-deoxyribose plus Y—OH. Alternatively those substrates may be phosphorylysed by nucleoside phosphorylase to yield ribose-1-phosphate plus Y—OH. The methods may be used to detect and/or assay parasites in biological samples.Type: ApplicationFiled: March 18, 2002Publication date: September 19, 2002Inventors: Vern L. Schramm, Richard Hubert Furneaux, Peter Charles Tyler, Keith Clinch
-
Publication number: 20020132364Abstract: Chemiluminescent endogenous enzyme assays which provide for the rapid, simple, and sensitive quantitation of cells directly in microwell cultures by the measurement of endogenous enzyme activity. These endogenous enzyme assays provide homogeneous chemiluminescent formats for measuring cell proliferation, growth inhibition, cell adhesion, cell migration, and cell number quantitation and normalization. Methods and kits employing such assays are also provided.Type: ApplicationFiled: January 9, 2001Publication date: September 19, 2002Inventors: Corinne E.M. Olesen, Yu-xin Yan, Irena Y. Bronstein
-
Patent number: 6451548Abstract: The invention relates to the use of activated TRAP (tartrate-resistant and purple acid phosphatases) for screening for specific inhibitor of TRAP activity useful in the treatment of diseases or degenerative conditions resulting in increased bone resorption, such as tissue damages, bone metabolic disorders, osteoporosis. TRAP can be activated by proteolytic activation of TRAP e.g. by cleaving with a protease, papain-like enzyme.Type: GrantFiled: November 18, 1999Date of Patent: September 17, 2002Assignee: Biovitrum ABInventors: Göran Andersson, Barbro Ek-Rylander, Cornelia Oellig
-
Publication number: 20020127628Abstract: The present invention relates to non-radioactive enzymatic methods for detecting Sphingosine-1-Phosphate (S1P) in biological fluids. The present invention further relates to a method of detecting the presence of cancer in a patient by the use of these and other methods of detecting S1P in biological samples from a patient.Type: ApplicationFiled: April 26, 2002Publication date: September 12, 2002Inventors: Michael K. Skinner, Jodi L. Johnson, Jeff A. Parrott
-
Patent number: 6448027Abstract: A method for measuring activity of osteoclast-derived acid phosphatase located at Band 5b of Band 5 in polyacrylamide gel electrophoresis of a sample which is characterized by using an inhibitor to acid phosphatases located at Band 5 other than Band 5b; and a composition and a kit for using in the method.Type: GrantFiled: June 26, 2000Date of Patent: September 10, 2002Assignee: FALCO biosystems Ltd.Inventors: Mamoru Nakanishi, Kagehiro Uchida
-
Patent number: 6440686Abstract: The present invention relates to protein modulators, especially modulators of kinesin bioactivities. The present invention provides methods for screening protein modulators, e.g., kinesin modulators that bind to a region of a kinesin and/or that modulate kinesin bioactivities. The present invention also provide methods and compositions for treatment of disorders mediated by abnormal cellular proliferation activities.Type: GrantFiled: June 15, 2000Date of Patent: August 27, 2002Assignee: Cytokinetics, Inc.Inventor: Roman Sakowicz
-
Patent number: 6440672Abstract: The invention relates to methods for identifying inhibitors of mucin production, methods for inhibiting mucin production and methods for treating airway diseases, such as cystic fibrosis, chronic bronchitis, bronchial pneumonia and asthma. Compositions are provided for use in the method comprising reporter gene constructs which are inducible by mucomones.Type: GrantFiled: April 20, 2000Date of Patent: August 27, 2002Assignee: The Regents of the University of CaliforniaInventors: Carol Basbaum, Marianne Gallup, Daizong Li, Assefa Gebremichael, Erin Gensch
-
Patent number: 6436637Abstract: The invention provides a human protein phosphatase (PROPHO) and polynucleotides which identify and encode PROPHO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PROPHO.Type: GrantFiled: December 7, 1998Date of Patent: August 20, 2002Assignee: Incyte Genomics, Inc.Inventors: Olga Bandman, Surya K. Goli, Preeti Lal, Neil C. Corley, Hong Zhang
-
Publication number: 20020106713Abstract: The present invention is related to an inhibitor of the inositol polyphosphate 5-phosphatase SHIP2 protein or its encoding nucleotide sequence identified by SEQ ID NO. 1 or of SHIP2 mRNA expression.Type: ApplicationFiled: August 3, 2001Publication date: August 8, 2002Inventors: Christopher Erneux, Stephane Schurmans
-
Publication number: 20020106714Abstract: The invention provides membrane molecule indicators, including polypeptides, encoding nucleic acid molecules and cells containing such polypeptides and nucleic acid molecules. The invention membrane molecule indicators are characterized in that fluorescence resonance energy transfer (FRET) between a donor fluorescent domain and an acceptor fluorescent domain indicates a property of the membrane molecule. Also provided are methods of using the invention membrane molecule indicators to determine a property of a membrane molecule, and to identify compounds that modulates a property of a membrane molecule.Type: ApplicationFiled: November 29, 2001Publication date: August 8, 2002Inventor: Kees Jalink
-
Patent number: 6428965Abstract: The semaphorin family contains a large number of plylogenetically conserved proteins and includes several members that have been shown to function in repulsive axon guidance. Semaplorin III (Sema III) is a secreted protein that in vitro causes neuronal growth cone collapse and chemorepulsion of neurites, and is required in vivo for correct sensory afferent innervation and other aspects of development. The mechanism of Sema III function, however, is unknown. Here, we report that neuropilin, a type I transmembrane protein, is a Sema III receptor. We also describe the identification of neuropiln-2, a related neuropilin family member, and show that neuropilin and neuropilin-2 are expressed in overlapping, yet distinct, populations of neurons in the rat embryonic nervous system.Type: GrantFiled: July 16, 1998Date of Patent: August 6, 2002Assignee: The Johns Hopkins UniversityInventors: David D. Ginty, Alex L. Kolodkin
-
Publication number: 20020102626Abstract: The present invention uses the principle that phosphomolybdate binds to hydrophobic surfaces to isolate the phosphomolybdate complex from other phosphate-containing molecules and further uses the SPA concept to bring a radiolabeled phosphomolybdate complex in close contact with a scintillant for measurement by scintillation counting. Generally, the present invention provides an assay for detecting and measuring the amount of orthophosphate (Pi) in an aqueous reaction mixture, wherein the amount of Pi released is separated from the reaction mixture by: adding a solution of molybdate to the reaction mixture to form a phosphomolybdate complex; and contacting the phosphomolybdate complex with a hydrophobic surface, wherein the surface is capable of being separated from the aqueous reaction mixture to allow measurement of the Pi. Particularly, this invention provides an assay for measuring the ATPase activity of enzymes, more particularly, the HPV E1 helicase.Type: ApplicationFiled: October 24, 2001Publication date: August 1, 2002Inventor: Peter White
-
Patent number: 6416716Abstract: The present invention relates to a novel device for small sample preparation using tubes and columns, such as capillaries or pipette tips, in which particles of a separation medium, such as particles of a chromatography material used for sample preparation, are directly embedded in the solid material composing the tubes or columns. Most small sample preparation methods currently available cannot prevent sample loss and they are not well suited for small sample volumes. The present invention minimizes sample loss and is well suited for samples with volumes in nanoliters. In the invention described herein, the desired sample, such as a sample composed of biomolecules, is brought in contact with particles of the separation medium embedded on the surface of the device comprised of tubes and columns, according to the present invention.Type: GrantFiled: April 20, 2001Date of Patent: July 9, 2002Inventors: Ashok Kumar Shukla, Mukta Shukla, Amita Shukla
-
Patent number: 6410255Abstract: This invention provides an optical probe useful as an optical probe or sensor of post translational type modifications, such as phosphorylation. The invention comprises a polypeptide moiety, which contains a recognition motif for a post translational type activity and a protease site, which is coupled to a probe moiety. Modification of the polypeptide, by the post translational type activity, results in a modulation of the rate at which a protease cleaves the polypeptide which is sensed by a measurable change in at least one optical property of the optical probe upon cleavage. The present invention also includes a recombinant nucleic acid molecule that encodes an optical probe and a vector and host cell or library of cells that include the recombinant nucleic acid molecule. The optical probe can be used in methods to determine whether a sample, including a cell or a sample from an organism, contains a post-translational type modification activity.Type: GrantFiled: May 5, 1999Date of Patent: June 25, 2002Assignee: Aurora Biosciences CorporationInventors: Brian A. Pollok, Brian D. Hamman, Steven M. Rodems, Lewis R. Makings
-
Patent number: 6410254Abstract: Described herein are methods which identify candidate agents as binding to a protein or as a modulator of the binding characteristics or biological activity of a protein. Generally, the methods involve the use of ADP or phosphate. The assays can be used in a high throughput system to obviate the cumbersome steps of using gels or radioactive materials.Type: GrantFiled: May 18, 1999Date of Patent: June 25, 2002Assignee: CytokineticsInventors: Jeffrey T. Finer, Fady Malik, Roman Sakowicz, Christopher Shumate, Kenneth Wood
-
Patent number: 6406869Abstract: A method for determining the level of tyrosine kinase activity in a biological sample is disclosed. The method employs an anti-phosphotyrosine antibody as both the capture agent and the detecting agent. The detecting antibody is labeled with a lanthanide ion, such as europium, as the signal generating entity. The method is particularly well suited to high throughput screening, for example, for compounds which modulate tyrosine kinase activity.Type: GrantFiled: October 22, 1999Date of Patent: June 18, 2002Assignee: Pharmacopeia, Inc.Inventors: J. Fraser Glickman, James Inglese, Bassam Damaj
-
Patent number: 6403330Abstract: A crystalline form of mammalian TRAP (tartrate-resistant and purple acid phosphatase) is described. The enzyme is activated by cleavage prior to crystallization with a protease and the crystalline form of the mammalian TRAP is capable of being used for X-ray studies.Type: GrantFiled: August 2, 2001Date of Patent: June 11, 2002Assignee: Biovitrum ABInventor: Jonas Uppenberg
-
Publication number: 20020064849Abstract: The present invention relates to a newly identified human soluble adenylyl cyclase and nucleic acid sequences encoding the adenylyl cyclase. The invention further relates to methods of using the adenylyl cyclase polypeptides and polynucleotides as a targets for identifying agonists and antagonists that are selective for human soluble adenylyl cyclase. Inhibitors of human soluble adenylyl cyclase can be used as contraceptive agents.Type: ApplicationFiled: September 5, 2001Publication date: May 30, 2002Inventors: John C. Herr, Pablo Visconti, Arabinda Mandal, Vrinda Khole
-
Patent number: 6391549Abstract: A method and system for detecting a parameter of a host cell, a cell culture or medium is provided. A host cell is transfected with an expressible DNA sequence which is under expression control of an inducible promoter sequence. The promoter sequence is inducible in correlation with the parameter, the expressible sequence encoding an enzymatically active product which can catalyze a reaction giving rise to an electrical signal which is detectable in an electrochemical measurement. An electrical signal determined in an electrochemical system then serves as an indication for the parameter.Type: GrantFiled: April 1, 1999Date of Patent: May 21, 2002Assignee: Ramont University Authority for Applied Research & Industrial Development Ltd.Inventors: Eliora Z. Ron, Judith Rishpon, Israel Biran, Reuven Babai
-
Patent number: 6387645Abstract: The invention provides novel polynucleotides isolated from cDNA libraries of human fetal liver-spleen and macrophage as well as polypeptides encoded by these polynucleotides and mutants or variants thereof. The polypeptides correspond to a novel human CD39-like protein. Other aspects of the invention include vectors containing polynucleotides of the invention and related host cells as well a processes for producing novel CD39-like polypeptides, and antibodies specific for such polypeptides.Type: GrantFiled: July 9, 1999Date of Patent: May 14, 2002Assignee: Hyseq, Inc.Inventors: John Ford, Julio J. Mulero
-
Publication number: 20020055149Abstract: Methods of performing fast polymerase mediated reactions are provided. These reactions can be used in an inefficient fashion in the cycles of the polymerase mediated reactions to produce product at a much faster rate than conventional polymerase mediated reaction methods. Integrated systems for performing these methods are also provided.Type: ApplicationFiled: August 29, 2001Publication date: May 9, 2002Inventor: Anne R. Kopf-Sill
-
Patent number: 6376211Abstract: Novel methods of identifying antimicrobial and anti-proliferative agents and therapeutic uses are provided.Type: GrantFiled: April 6, 2000Date of Patent: April 23, 2002Assignee: XOMA Technology Ltd.Inventors: Roger G. Little, II, Susan Abrahamson
-
Publication number: 20020042081Abstract: The present invention is a method for selectively removing objects from a surface utilizing a probe. The probe is scanned over the surface utilizing a greater and greater relative amount of force so that a certain number of the objects are removed from the surface. The force required to remove the objects from the surface can be calculated utilizing Hook's law and the spring constant of the probe. After removal of the objects that have a relatively weaker binding affinity with the surface, the remaining objects can be harvested, characterized, and subjected to further study.Type: ApplicationFiled: October 9, 2001Publication date: April 11, 2002Inventors: Eric Henderson, Curtis Mosher
-
Patent number: 6365366Abstract: T2K kinase activity is detected by forming a mixture of a T2K kinase and a substrate; incubating the mixture under conditions whereby the kinase phosphorylates the substrate at a first rate; and detecting the first rate as an indication of the kinase activity. The substrate comprises SX1X2X3SX4 (SEQ ID NO:1) wherein X1 and X4 are aliphatic residues and both of the S residues are targets of the kinase, and especially, IKK&agr; or IKK&bgr;. In another embodiment, the mixture substrate comprises a particular IL-1 or TNF signaling cascade component. The mixture may be used to screen for agents which modulate the activity of the kinase, e.g. as an immuno-chemiluminescent assay.Type: GrantFiled: March 13, 2000Date of Patent: April 2, 2002Assignee: Tularik Inc.Inventor: Zhaodan Cao
-
Patent number: 6355447Abstract: The invention provides isolated nucleic acid and amino acid sequences of HsKif9, antibodies to HsKif9, methods of screening for HsKif9 modulators using biologically active HsKif9, and kits for screening for HsKif9 modulators.Type: GrantFiled: November 27, 2000Date of Patent: March 12, 2002Assignee: Cytokinetics, Inc.Inventors: Christophe Beraud, Richard Freedman
-
Patent number: 6352830Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: January 15, 1999Date of Patent: March 5, 2002Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho, William M. Flanagan
-
Patent number: 6350601Abstract: Disclosed is a stabilized enzyme composition for use in clinical examination, comprising: (a) an enzyme component comprising at least two enzymes selected from the group consisting of alkaline phosphatase, creatine kinase and alanine aminotransferase; (b) a stabilizer component comprising effective stabilizing amounts of an albumin, and at least one saccharide selected from the group consisting of trehalose and sorbitol; and (c) an aqueous medium having dissolved therein the components (a) and (b). The enzyme composition of the present invention is stable for a prolonged period of time not only under non-freeze refrigeration conditions, but also under freezing conditions or under conditions for non-freeze refrigeration after thawing of the frozen composition, as compared to the conventional enzymatic compositions.Type: GrantFiled: May 8, 1997Date of Patent: February 26, 2002Assignee: Asahi Kasei Kogyo Kabushiki KaishaInventors: Ryoji Aoki, Shigeru Ueda
-
Publication number: 20020009762Abstract: The invention relates in part to screening assays for identifying agents that alter the interaction between a protein tyrosine phosphatase (PTP) and its tyrosine phosphorylated polypeptide substrate, using fluorescence energy signals generated by detectably labeled substrates. Assays are provided in certain embodiments, including high throughput screening assays, wherein candidate agents are screened by fluorescence polarization for their ability to influence (i) binding of substrate trapping mutant PTPs to substrates, or (ii) dephosphorylation of tyrosine phosphorylated substrates by PTPs.Type: ApplicationFiled: February 13, 2001Publication date: January 24, 2002Inventors: Andrew J. Flint, Deborah E. Cool
-
Publication number: 20020007046Abstract: The invention provides a human cyclic GMP phosphodiesterase (PDE9A) and polynucleotides which identify and encode PDE9A. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE9A.Type: ApplicationFiled: March 8, 2001Publication date: January 17, 2002Applicant: Incyte Pharmaceuticals, Inc.Inventors: Douglas A. Fisher, Douglas H. Gooding, David Gray Streeter
-
Publication number: 20020004218Abstract: The present invention relates to methods for identifying compounds useful as inhibitors of geranylgeranyl diphosphate synthase. More particularly, the compounds so identified are useful for inhibiting bone resorption. The present invention also relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a geranylgeranyl diphosphate synthase inhibitor.Type: ApplicationFiled: March 26, 2001Publication date: January 10, 2002Inventors: Gideon A. Rodan, Alfred A. Reszka
-
Publication number: 20010055784Abstract: Amounts of components in a specimen can be analyzed with excellent quantitativity. The analysis includes: measuring an amount of a component to be analyzed in a specimen; measuring an amount of a standard component present originally and homeostatically in the specimen other than the component to be analyzed; determining the amount of the specimen from the amount of the standard component thus measured and a known concentration of the standard component in the specimen; and determining a concentration of the component to be analyzed in the specimen from the amount of the specimen thus determined and the amount of the component to be analyzed thus measured. The quantitative analysis of the present invention allows a component to be analyzed to be measured with high quantitativity as shown in FIG. 1.Type: ApplicationFiled: May 16, 2001Publication date: December 27, 2001Applicant: ARKRAY, Inc.Inventors: Yuichiro Noda, Yoshiyuki Tanaka, Konomu Hirao
-
Patent number: 6326159Abstract: Receptors are disclosed that are antibodies that exhibit a binding affinity for an immune complex of a monoepitopic antigen and an antibody for such antigen that is substantially greater than the binding affinity for the monoepitopic antigen or the antibody for the monoepitopic antigen apart from the immune complex. Normally, the monoepitopic antigen has a molecular weight less than 1500 and is an organic compound. The antibodies of the present invention find use in a method for determining a monoepitopic antigen in a sample suspected of containing such antigen. The method comprises forming an immune sandwich complex comprising the monoepitopic antigen or an analog thereof, a first monoclonal antibody that binds to the monoepitopic antigen, and a second monoclonal antibody that is an antibody of the present invention and detecting the immune sandwich complex.Type: GrantFiled: September 2, 1994Date of Patent: December 4, 2001Assignee: Dade Behring Marburg GmbHInventors: Edwin F. Ullman, John Jelesko, Marcel R. Pirio, Thomas D. Kempe
-
Patent number: 6322975Abstract: The present invention makes available assays and reagents for identifying agents which can be used to modulate at least one proliferation, differentiation and cell death by apoptosis.Type: GrantFiled: January 15, 1999Date of Patent: November 27, 2001Inventors: David H. Beach, Konstantin Galaktionov
-
Patent number: 6306642Abstract: One-step enzyme immunoassays in which enzyme-antibody conjugate or label and enzyme substrate are separated until separation of bound and free enzyme conjugate or label is complete. This separation is accomplished by using variable flow paths, immobilization of substrate at the test line, placement of substrate in a sac or association with a particle label, enzyme product chemical capture, delay zone dissolution and protected enzyme substrates.Type: GrantFiled: November 24, 1997Date of Patent: October 23, 2001Assignee: Quidel CorporationInventors: Alan M. Nelson, Jan W. Pawlak, Allan D. Pronovost
-
Patent number: 6303343Abstract: Methods of performing fast polymerase mediated reactions are provided. These reactions can be used in an inefficient fashion in the cycles of the polymerase mediated reactions to produce product at a much faster rate than conventional polymerase mediated reaction methods. Integrated systems for performing these methods are also provided.Type: GrantFiled: April 6, 1999Date of Patent: October 16, 2001Assignee: Caliper Technologies Corp.Inventor: Anne R. Kopf-Sill
-
Patent number: 6296848Abstract: The present invention generally relates to novel GRB2 associating proteins and nucleic acids which encode these protein. In particular, these novel proteins possess inositol polyphosphate 5-phosphatase and phosphatidylinositol 5-phosphatase activities, important in growth factor mediated signal transduction. As such, the proteins, nucleic acids encoding the proteins, cells capable of expressing these nucleic acids and antibodies specific for these proteins will find a variety of uses in a variety of screening, therapeutic and other applications.Type: GrantFiled: October 14, 1999Date of Patent: October 2, 2001Assignee: The Regents of the University of CaliforniaInventors: David A. Pot, Lewis T. Williams, Anne Bennett Jefferson, Philip W. Majerus
-
Patent number: 6291200Abstract: A sensor for detecting the presence of at least one analyte includes at least one enzyme that is selected to either (i) catalyze a reaction of the analyte to chemically convert the analyte to a product compound or (ii) be inhibited by the analyte in the presence of a substrate compound. The sensor also includes at least one indicator compound selected to produce a measurable change of state as a result of the interaction of the analyte and the enzyme. Each of the enzyme and the indicator compound are incorporated within a single polymer.Type: GrantFiled: November 17, 1999Date of Patent: September 18, 2001Assignee: Agentase, LLCInventors: Keith E. LeJeune, Alan J. Russell
-
Patent number: 6284480Abstract: The present invention provides high throughput screening systems for identifying antifungal compounds. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts.Type: GrantFiled: April 3, 2000Date of Patent: September 4, 2001Assignee: Cytokinetics, Inc.Inventors: Corey E. Nislow, Roman Sakowicz, Christophe Beraud
-
Publication number: 20010018196Abstract: Method for identifying compounds that inhibit cytokinesis, wherein the compounds are tested for their ability to modulate the formation and/or the stability of septin filaments. The compounds are useful in tumor therapy.Type: ApplicationFiled: December 7, 2000Publication date: August 30, 2001Inventors: Manuel Mendoza, Michael Glotzer
-
Patent number: 6280965Abstract: The present invention is a simple, selective, rapid and a non-radioactive procedure for estimating the activity of protein kinases and protein phosphatases. The method involves attaching a suitable substrate to a 96-well plate surface and then measuring the activity of the specific enzymes using suitable incubating conditions. The PKC assay involves immobilizing histone (type III-SS), the substrate for PKC, and then determining the extent of phosphorylation by using ammonium molybdate and 1-amino-2-naphthol-4-sulfonic acid based reaction for inorganic phosphate quantitation. The PP-1 assay involves immobilizing phosphorylase-b substrate to the assay plate and then phosphorylating the substrate using phosphorylase kinase. Finally, the phosphate is hydrolyzed from the substrate by protein phosphatase. The assay methods are suitable for estimating PKC and PP-1 activity in tissue and cell samples without using any radiolabeled substrate.Type: GrantFiled: May 26, 1999Date of Patent: August 28, 2001Assignee: Nova Southeastern UniversityInventors: Appu Rathinavelu, Andres Malave
-
Patent number: 6274309Abstract: The present invention relates, first, to methods and compositions for the modulation of acid sphingomyelinase (ASM)-related processes, including apoptosis. Such apoptosis can include, but is not limited to, environmental stress-induced apoptosis such as, for example, ionizing radiation and/or chemotherapeutic agent-induced apoptosis. Apoptosis can be characterized by a cellular morphology comprising cellular condensation, nuclear condensation or zeiosis. The present invention further relates to methods for the identification of compounds which modulate (i.e., either increase or decrease) sensitivity to ASM-related processes, including apoptosis.Type: GrantFiled: July 26, 1996Date of Patent: August 14, 2001Inventors: Richard Kolesnick, Edward H. Schuchman
-
Patent number: 6274327Abstract: This invention relates to new polypeptides which exhibit kinase activity or, more specifically, which show phosphoinositide (PI) 3-kinase activity. Such polypeptides are involved in pathways responsible for cellular growth and differentiation. An isolated polypeptide which possesses PI3-kinase activity when produced by recombinant production in insect cells is disclosed.Type: GrantFiled: May 27, 1998Date of Patent: August 14, 2001Assignee: Ludwig Institute for Cancer ResearchInventors: Ian D. Hiles, Michael J. Fry, Ritu Dhand, Michael D. Waterfield, Peter J. Parker, Masayuki Otsu, George Panayoutou, Stefano Volinia, Ivan Gout